Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica

Molecular Immunology

Volumn 62, Issue 1, 2014, Pages 104-113

  Ratelade, Julien ^a   Verkman, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AQP4 IgG; Aquaporin 4; Complement dependent cytotoxicity; Mouse models; NMO

Indexed keywords

ALPHA 1 ANTITRYPSIN 1 1; ALPHA 1 ANTITRYPSIN 1 2; ALPHA 1 ANTITRYPSIN 1 4; ALPHA 2 MACROGLOBULIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOA1 PROTEIN; APOLIPOPROTEIN C3; AQUAPORIN 4 ANTIBODY; CARBOXYLESTERASE 1C; CERULOPLASMIN; COMPLEMENT C1Q SUBCOMPONENT SUBUNIT B; COMPLEMENT C1Q SUBCOMPONENT SUBUNIT C; COMPLEMENT C1S B; COMPLEMENT COMPONENT 1 R SUBCOMPONENT; COMPLEMENT COMPONENT 1 S SUBCOMPONENT; COMPLEMENT COMPONENT C3; IG HEAVY CHAIN V; IGH PROTEIN; IGHG PROTEIN; IMMUNOGLOBULIN G; KININOGEN I; MANNAN BINDING LECTIN SERINE PROTEASE 1; MANNOSE BINDING PROTEIN C; PLASMA KALLIKREIN; PROPERDIN; PROTEIN; PROTEIN A; SERINE PROTEASE INHIBITOR A3 K; SEROTRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; AQUAPORIN 4; AUTOANTIBODY; COMPLEMENT INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; EXPERIMENTAL MOUSE; FEMALE; GUINEA PIG; HEMOLYSIS; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOUSE; MYELOOPTIC NEUROPATHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; SERUM; SPECIES COMPARISON; ANIMAL; BLOOD; C57BL MOUSE; CHO CELL LINE; CRICETULUS; DISEASE MODEL; IMMUNOLOGY; TRANSGENIC MOUSE; WISTAR RAT;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; CHO CELLS; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, CLASSICAL; CRICETULUS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROMYELITIS OPTICA; RATS; RATS, WISTAR;

EID: 84903381521     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.06.003     Document Type: Article

References (41)

1. de Seze J., Stojkovic T., Ferriby D., Gauvrit J.Y., Montagne C., Mounier-Vehier F., Verier A., Pruvo J.P., Hache J.C., Vermersch P. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J. Neurol. Sci. 2002, 197:57-61.
2. Jacob A., McKeon A., Nakashima I., Sato D.K., Elsone L., Fujihara K., de Seze J. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J. Neurol. Neurosurg. Psychiatry 2013, 84:922-930.
3. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-815.
4. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
5. Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. J. Neurol. Sci. 2011, 306:183-187.
6. Jarius S., Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 2010, 6:383-392.
7. Papadopoulos M.C. Verkman AS: Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012, 11:535-544.
8. Bennett J.L., Lam C., Kalluri S.R., Saikali P., Bautista K., Dupree C., Glogowska M., Case D., Antel J.P., Owens G.P., Gilden D., Nessler S., Stadelmann C., Hemmer B. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66:617-629.
9. Ratelade J., Asavapanumas N., Ritchie A.M., Wemlinger S., Bennett J.L., Verkman A.S. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. 2013, 126:699-709.
10. Vincent T., Saikali P., Cayrol R., Roth A.D., Bar-Or A., Prat A., Antel J.P. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J. Immunol. 2008, 181:5730-5737.
11. Pohl M., Fischer M.T., Mader S., Schanda K., Kitic M., Sharma R., Wimmer I., Misu T., Fujihara K., Reindl M., Lassmann H., Bradl M. Pathogenic T cell responses against aquaporin 4. Acta Neuropathol. 2011, 122:21-34.
12. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., Adzemovic M., Bauer J., Berger T., Fujihara K., Itoyama Y., Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
13. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata K., Okuno T., Kumanogoh A., Kajiyama K., Yoshikawa H., Sakoda S. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 2009, 386:623-627.
14. Kimura A., Hsu M., Seldin M., Verkman A.S., Scharfman H.E., Binder D.K. Protective role of aquaporin-4 water channels after contusion spinal cord injury. Ann. Neurol. 2010, 67:794-801.
15. Saadoun S., Waters P., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
16. Saadoun S., Waters P., Macdonald C., Bell B.A., Vincent A., Verkman A.S., Papadopoulos M.C. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann. Neurol. 2012, 71:323-333.
17. Zhang H., Verkman A.S. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J. Clin. Invest. 2013, 123:2306-2316.
18. Tradtrantip L., Ratelade J., Zhang H., Verkman A.S. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann. Neurol. 2013, 73:77-85.
19. Tradtrantip L., Zhang H., Saadoun S., Phuan P.W., Lam C., Papadopoulos M.C., Bennett J.L., Verkman A.S. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann. Neurol. 2012, 71:314-322.
20. Asavapanumas N., Ratelade J., Papadopoulos M.C., Bennett J.L., Levin M.H., Verkman A.S. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. J. Neuroinflamm. 2014, 11:16.
21. Zhang H., Verkman A.S. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J. Autoimmun 2014, 10.1016/j.jaut.2014.02.011.
22. Bettelli E., Baeten D., Jager A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 2006, 116:2393-2402.
23. Krishnamoorthy G., Lassmann H., Wekerle H., Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 2006, 116:2385-2392.
24. Ratelade J., Bennett J.L., Verkman A.S. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS ONE 2011, 6:e27412.
25. Bergman I., Basse P.H., Barmada M.A., Griffin J.A., Cheung N.K. Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. Cancer Immunol. Immunother. 2000, 49:259-266.
26. Crane J.M., Lam C., Rossi A., Gupta T., Bennett J.L., Verkman A.S. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 m1/m23 isoforms and orthogonal arrays. J. Biol. Chem. 2011, 286:16516-16524.
27. Guan, S., Price, J.C., Prusiner, S.B., Ghaemmaghami, S., Burlingame, A.L., 2011. A data processing pipeline for mammalian proteome dynamics studies using stable isotope metabolic labeling. Mol. Cell Proteomics 10, M111 010728.
28. Ong G.L., Mattes M.J. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Methods 1989, 125:147-158.
29. Phuan P.W., Zhang H., Asavapanumas N., Leviten M., Rosenthal A., Tradtrantip L., Verkman A.S. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol. 2013, 125:829-840.
30. Hitsumoto Y., Okada M., Makino H. Inhibition of human and mouse complement-dependent hemolytic activity by mouse fibronectin. Immunopharmacology 1999, 42:203-208.
31. Mandle R.J., McConnell-Mapes J.A., Nilsson U.R. Inhibition of complement by mouse serum: selective inactivation of the fourth component of human complement. J. Immunol. 1977, 119:180-186.
32. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
33. Holers V.M. The spectrum of complement alternative pathway-mediated diseases. Immunol. Rev. 2008, 223:300-316.
34. Ebanks R.O., Isenman D.E. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol. Immunol. 1996, 33:297-309.
35. Lachmann P.J. Preparing serum for functional complement assays. J. Immunol. Methods 2010, 352:195-197.
36. Baba A., Fujita T., Tamura N. Sexual dimorphism of the fifth component of mouse complement. J. Exp. Med. 1984, 160:411-419.
37. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E., Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
38. Asavapanumas N., Ratelade J., Verkman A.S. Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG. Acta Neuropathol. 2014, 127:539-551.
39. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998, 19:56-59.
40. Nayak A., Ferluga J., Tsolaki A.G., Kishore U. The non-classical functions of the classical complement pathway recognition subcomponent C1q. Immunol. Lett. 2010, 131:139-150.
41. Rose K.L., Paixao-Cavalcante D., Fish J., Manderson A.P., Malik T.H., Bygrave A.E., Lin T., Sacks S.H., Walport M.J., Cook H.T., Botto M., Pickering M.C. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J. Clin. Invest. 2008, 118:608-618.